×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALT – altimmune, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
06:18 am
alt
Altimmune (ALT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Medium
Report
Altimmune (ALT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
3/24
11:05 am
alt
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Low
Report
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
3/18
04:00 pm
alt
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Neutral
Report
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
3/16
12:23 pm
alt
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
3/12
12:02 pm
alt
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]
Low
Report
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]
3/11
07:58 pm
alt
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
Medium
Report
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
3/6
11:34 am
alt
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
3/6
08:40 am
alt
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
Low
Report
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/6
04:05 pm
alt
Form 4 Altimmune, Inc. For: Apr 06 Filed by: GILL JOHN
Low
Report
Form 4 Altimmune, Inc. For: Apr 06 Filed by: GILL JOHN
4/1
04:05 pm
alt
Form 4 Altimmune, Inc. For: Apr 01 Filed by: Durso Jerome Benedict
Low
Report
Form 4 Altimmune, Inc. For: Apr 01 Filed by: Durso Jerome Benedict
4/1
04:05 pm
alt
Form 4 Altimmune, Inc. For: Apr 01 Filed by: WEAVER GREGORY L
Low
Report
Form 4 Altimmune, Inc. For: Apr 01 Filed by: WEAVER GREGORY L
3/26
03:24 pm
alt
Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC
3/17
07:13 am
alt
Form ARS Altimmune, Inc. For: Dec 31
Low
Report
Form ARS Altimmune, Inc. For: Dec 31
3/17
07:05 am
alt
Form DEF 14A Altimmune, Inc. For: Apr 16
Low
Report
Form DEF 14A Altimmune, Inc. For: Apr 16
3/9
07:05 am
alt
Form 4 Altimmune, Inc. For: Mar 06 Filed by: WEAVER GREGORY L
Medium
Report
Form 4 Altimmune, Inc. For: Mar 06 Filed by: WEAVER GREGORY L
3/9
07:00 am
alt
Form 4 Altimmune, Inc. For: Mar 06 Filed by: Durso Jerome Benedict
Medium
Report
Form 4 Altimmune, Inc. For: Mar 06 Filed by: Durso Jerome Benedict
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
29.8%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
TOP News Decliners
3/9
Thinking about buying stock in Aurora Cannabis, Altimmune, Chesapeake Energy Corp, Nokia, or Sprint?
-20.8%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: